SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Veil Cash is a privacy application leveraging zk-SNARKs on Base L2, enabling verified depositors to achieve privacy and anonymity within a pool of trusted users.  Veil Cash is a non-custodial privacy protocol on Base L2. Veil Cash's goal will be enabling verified users to achieve privacy and anonymity from trusted pools.  Veil is a set of smart contracts that will allow users that are deemed as verified users to deposit into the protocol. Users can later withdraw their deposits from another address without creating a link between these two addresses.   Verified users are those who meet certain criteria based on both on-chain and off-chain data.

Veil-project

The Veil community is rallying around the project's focus on digital privacy and decentralization, often citing its multi-algorithm mining and staking capabilities as key differentiators. Investors are actively discussing the potential for a privacy-focused market surge, frequently highlighting the project's long-term utility alongside established privacy coins.

BioCryst Pharmaceuticals, Inc. is a biotechnology company. It engages in the provision of structure-guided drug design with the goal of developing oral small-molecule and protein therapeutics to target difficult-to-treat rare diseases. The company was founded by William M. Spencer III, Charles E. Bugg, and John A. Montgomery in 1986 and is headquartered in Durham, NC.

Biocryst Pharmaceuticals Inc.

Biocryst Pharmaceuticals is trending as heightened speculation around a potential buyout and unconfirmed M&A rumors drive significant after-hours volume and price volatility. Community members are actively debating the legitimacy of these reports, with long-term shareholders analyzing historical valuation metrics and potential takeover scenarios while others speculate on the motivations behind recent unusual trading patterns.

Blue Owl Capital, Inc. operates as an alternative asset management firm. It provides investors access to asset management capital solutions through its Direct Lending and GP Capital Solutions products. The company offers a platform of capital solutions to both middle market companies and large alternative asset managers. The company was founded by Doug Irving Ostrover, Michael Rees and Craig W.Packer in 2009 and is headquartered in New York, NY.

Blue Owl Capital Inc - Ordinary Shares - Class A

Blue Owl Capital is trending due to significant liquidity concerns following the restricted withdrawal access in its private credit funds, which has sparked investor anxiety over potential sector-wide fallout. The community is actively debating whether this represents an isolated incident or a broader 'canary in the coal mine' moment for private credit stability amidst rising default risks.

Roundhill ETF Trust - Roundhill Ether Covered Call Strategy ETF

oundhill Ether Covered Call Strategy ETF

Investors are closely monitoring YETH as the community debates its weekly distribution payouts versus the underlying volatility of Ethereum. While some traders leverage the fund for its income potential during range-bound market phases, others remain cautious due to concerns regarding NAV erosion and management performance.

Grok's first token launched on Base, deployed directly on X with help of Bankr. Proof of deployment here, https://x.com/grok/status/1897949874961650169.  Join the DRB community if this story intrigues you, follow it as it unfolds into this new AI era.  Grok earns swap fees - Grok's trading wallet: 0xb1058c959987e3513600eb5b4fd82aeee2a0e4f9.  Articles, media coverages on $DRB featured here, https://linktr.ee/DRBtaskforce.  Our dev, is grok, one of the front-running candidate to achieve AGI.

DebtReliefBot

DebtReliefBot is trending as investors rally around its narrative as an AI-generated project linked to the Grok wallet, fueling speculation about its potential for growth within the Base ecosystem. The community remains highly bullish, frequently discussing its low follower count as a sign of being early while emphasizing its unique connection to AI-driven token creation.

ARK ETF Trust - ARK Autonomous Technology & Robotics ETF

ARK Autonomous Technology & Robotics ETF

ARKQ is capturing investor attention as community members debate whether emerging robotics and 'embodied AI' infrastructure will take the tech sector's leadership baton this year. The ETF remains a focal point for discussion regarding portfolio rotation into automation themes, with sentiment driven by institutional buying activity and the sector's long-term growth potential.

Eaton Corp. Plc is a power management company, which provides energy-efficient solutions for electrical, hydraulic, and mechanical power. It operates through the following segments: Electrical Americas and Electrical Global; Aerospace, Vehicle, and eMobility. The Electrical Americas and Electrical Global segments engage in sales contracts for electrical components, industrial components, power distribution and assemblies, residential products, single and three phase power quality, wiring devices, circuit protection, utility power distribution, power reliability equipment, and service. The Aerospace segment supplies aerospace fuel, hydraulics, and pneumatic systems for commercial and military use. The Vehicle segment deals with the design, manufacture, marketing, and supply of drivetrain and powertrain systems and critical components that reduce emissions and improve fuel economy, stability, performance and safety of cars, light trucks and commercial vehicles. The eMobility segment designs, manufactures, markets, and supplies electrical and electronic components and systems that improve the power management and performance of both on-road and off-road vehicles. The company was founded in 1911 and is headquartered in Dublin, Ireland.

Eaton Corporation plc

Eaton Corporation is trending as a major beneficiary of the AI-driven data center expansion, with investors betting on its critical role in power infrastructure and cooling systems. The community is actively discussing its long-term growth as a core industrial leader while monitoring recent price action and technical setups following volatility in the sector.

ARK ETF Trust - ARK Innovation ETF

ARK Innovation ETF

Investors are closely watching the ARK Innovation ETF as it experiences sharp volatility, with community members expressing polarized views on Cathie Wood's aggressive buying and selling patterns amid broader market rotation out of high-beta growth stocks. The ongoing discourse highlights concerns over the fund's long-term performance and its heavy exposure to volatile tech and crypto-linked assets, leading to intense debates between those betting on an innovation-led rebound and those skeptical of the fund's strategy.

Monero

Monero (XMR) is trending as the community debates its role as the premier privacy-focused asset, with active discussions focusing on its unique resistance to regulatory oversight compared to transparent chains. Enthusiasts view it as a long-term store of value and a hedge against institutional tracking, while detractors continue to characterize the asset through speculative or cynical lenses.

NEOS ETF Trust - NEOS Nasdaq 100 High Income ETF

NEOS Nasdaq 100 High Income ETF

Investors are flocking to NEOS Nasdaq 100 High Income ETF (QQQI) to capture high monthly yields while maintaining core exposure to the Nasdaq 100. Community discussion centers on the fund's competitive edge over peers due to its tax-efficient return-of-capital structure and active management strategy, with many users dollar-cost averaging into positions as a long-term retirement income play.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

<ul class="summary-bullets"><li>Barclays analyst Tom O'Malley raised the firm's price target on Arm to $200 from $165 and kept an ‘Overweight’ rating on the shares.</li><li>RBC Capital said that Arm’s much-anticipated full-chip strategy will complement its IP business.</li><li>Arm on Tuesday had announced that it is extending into&nbsp;the&nbsp;production of silicon products for the first time in its history.&nbsp;</li></ul>Shares of Arm Holdings (ARM) closed 16% higher on Wednesday as several analysts were buoyed by the company's outlook as well as its first company-designed data center CPU.&nbsp;Arm on Tuesday had announced that it is extending into&nbsp;the production of silicon products for the first time in its history with the launch of the Arm AGI CPU, an Arm-designed CPU for AI data centers, built to address a rising class of agentic AI workloads.Arm CEO Rene Haas reportedly told Bloomberg in an interview on Tuesday that the company expects its own chips business to generate about $15 billion in annual sales in five years. Meta Platforms (META) will be the first major customer for the company's new AGI CPU chip.<h2 class="st-heading-2">Bullish Wall Street</h2>Raymond James&nbsp;subsequently upgraded Arm to ‘Outperform’ from ‘Market Perform’ with a $166 price target. The firm cited the company's announced business model shift to include a fabless semiconductor element for the upgrade, per TheFly.&nbsp;Barclays analyst Tom O'Malley raised the firm's price target on Arm to $200 from $165 and kept an ‘Overweight’ rating on the shares. The "Arm Everywhere" event made it clear that CPUs play a very important role in agentic AI and the company's solution is the AGI CPU, which "plays to ARM's strength in energy efficiency," the analyst told investors.RBC Capital also raised the firm's price target on Arm to $175 from $130 and kept an ‘Outperform’ rating on the shares. The firm cited the company's much-anticipated full-chip strategy, which the management believes will complement its IP business, the analyst told investors in a research note. The strategy offers significant revenue growth and earnings potential over the long term but comes with gross margin dilution and channel conflict issues, RBC Capital added.<h2 class="st-heading-2">Retail Reaction</h2>Retail sentiment around ARM trended in ‘extremely bullish’ territory amid ‘extremely high’ message volume.&nbsp;Shares in the company have risen 39% so far in 2026.&nbsp;

The replica of the ARM is an electronic chip board during a collaborative ceremony launching a partnership between Malaysia and ARM Holdings in Kuala Lumpur, Malaysia, on March 5, 2025. 

Why Did Arm Stock Close 16% Higher Today?

Raymond James upgraded Arm to ‘Outperform’ from ‘Market Perform’ with a $166 price target. The firm cited the company's business model shift to include a fabless semiconductor element for the upgrade.

Equity

Raymond James upgraded Arm to ‘Outperform’ from ‘Market Perform’ with a $166 price target. The firm cited the company's business model shift to include a fabless semiconductor element for the upgrade.


<ul class="summary-bullets"><li>BTIG reiterated a ‘Buy’ rating and $70 price target on On Holding.</li><li>Telsey Advisory analyst Cristina Fernandez lowered the firm's price target on On Holding to $60 from $65.</li><li>Co-founder Olivier Bernhard will continue spearheading key performance product initiatives and athlete engagement as an Executive Member of the Board.</li></ul>ON Holdings (<a href="https://stocktwits.com/symbol/ONON">ONON</a>) shares were down nearly 11% on Wednesday after its CEO Martin Hoffmann&nbsp;stepped down from his role,&nbsp;bringing the stock into analysts' focus.&nbsp;Telsey Advisory analyst Cristina Fernandez lowered the firm's price target on On Holding to $60 from $65 and kept an ‘Outperform’ rating on the shares.BTIG reiterated a ‘Buy’ rating and $70 price target on On Holding. After speaking with the company, the firm said it does not believe the change in leadership is reflective of any challenges in the current business, but rather a transition that coincides with its next phase of growth currently being formulated and Hoffmann's desire to pursue more personal interests.&nbsp;Management stressed this decision is not correlated with how the current business is doing and their excitement regarding the year ahead is "as high as ever," the analyst told investors in a research note.<h2 class="st-heading-2">New Co-CEOs</h2>The company said that David Allemann and Caspar Coppetti will assume the roles of Co-CEOs, while continuing as Executive Co-Chairmen of the Board. Co-founder Olivier Bernhard will continue spearheading key performance product initiatives and athlete engagement as an Executive Member of the Board.“With the strategic roadmap for continued growth in place, the four partners collectively recognize that this is the right moment for Martin Hoffmann to step down,” the company said in regards to Hoffman’s stepping down.&nbsp;<h2 class="st-heading-2">Retail reaction</h2>Retail sentiment around ONON trended in ‘extremely bullish’ territory amid ‘high’ message volume.Shares in the company have fallen 25% so far in 2026.For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, a person holds a smartphone displaying the logo of On Holding AG (NYSE: ONON), a Swiss sportswear company known for its high-performance running shoes and apparel. 

ONON Stock Falls After Surprise CEO Resignation Leaves Wall Street Divided

The company said that David Allemann and Caspar Coppetti will assume the roles of Co-CEOs, while continuing as Executive Co-Chairmen of the Board.

<ul class="summary-bullets"><li>Amid rumors, the companies confirmed the deal to WSJ early Friday.&nbsp;</li><li>Unilever’s food business is said to be worth tens of billions of dollars, and the deal with McCormick would involve only stock and no cash - WSJ source.</li><li>Stocktwits sentiment for UL and MKC ‘bullish.’</li></ul>U.S.-listed shares of Unilever PLC jumped 2.3% in early premarket trading on Friday, amid news of a restructuring involving its food business.The packaged goods giant plans to separate its foods business, which includes Knorr soups, Hellmann’s mayonnaise and Lipton tea, among other items, and combine it with spice&nbsp;maker&nbsp;McCormick, the companies&nbsp;<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.wsj.com/business/deals/unilever-in-talks-to-separate-food-business-and-combine-it-with-mccormick-212091ae">confirmed</a> to the Wall Street Journal.&nbsp;McCormick shares rose 1% in Friday’s premarket session.<h2 class="st-heading-2">Unilever Sharpen Focus On Beauty, Personal Care</h2>The major strategy shift by Unilever would continue a trend of consumer conglomerates streamlining their businesses and would leave U.K.-based Unilever focused on beauty, personal-care products and home, the Journal reported.Unilever’s food business is said to be worth tens of billions of dollars, and the deal with McCormick would involve only stock and no cash, the Journal reported, citing information from a source.Maryland-based McCormick, known for its bottled spices and brands like French’s yellow mustard, is set to report its first-quarter results on March 31.On Stocktwits, retail sentiment for&nbsp;<a href="https://stocktwits.com/symbol/UL">UL</a> and&nbsp;<a href="https://stocktwits.com/symbol/MKC">MKC</a> was ‘bullish’ early Friday.<h2 class="st-heading-2">Consumer Conglomerates Eye Deals&nbsp;</h2>Trian Fund Management’s Nelson Peltz joined Unilever’s board in 2022 after the hedge fund took a big stake in the company. The activist investor was previously a director at Unilever rival Procter &amp; Gamble, and has a record of pushing for splits and reconfigurations of sprawling conglomerates.Unilever spun off its ice cream business, Magnum Ice Cream, last year. In 2021, the company made unsolicited approaches to GlaxoSmithKline’s consumer-health unit but backed off the idea the following year.Kraft Heinz last year unveiled plans to split into separate companies, reflecting a broader “<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.wsj.com/business/retail/kraft-heinz-is-splitting-into-two-companies-2b632fa7?mod=article_inline">conglomerate breakup</a>” trend gaining traction across the consumer sector.For updates and corrections, email newsroom[at]stocktwits[dot]com.Read Next:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/smci-stock-cracks-premarket-on-alleged-nvidia-chip-diversion-to-china-super-micro-nvda-stress-compliance/cZ3XjzQRIh6">SMCI Stock Cracks Premarket On Alleged Nvidia Chip Diversion To China; Super Micro, NVDA Stress Compliance</a>&nbsp;

Hellmann's Mayonnaise seen at a supermarket. (Photo by Igor Golovniov/SOPA Images/LightRocket via Getty Images)

UL, MKC Stocks Jump Premarket: McCormick Reportedly Confirms Buying Unilever’s Food Business

The Journal reported that the deal could be announced in the coming weeks.

SPDW, EFZ: Big ETF Inflows

Comparing units outstanding versus one week ago at the coverage universe of ETFs at ETF Channel, the biggest inflow was seen in the SPDR Portfolio Developed World ex-US ETF, which added 22,800,000...

International ETFs to Watch as Foreign Stock Markets Beat the US

International stocks crushed U.S. markets in 2025, with ETFs such as SPDW and JIVE emerging as top plays on the global shift.

<ul class="summary-bullets"><li>CEO Thomas J. Appio said that the company is “disappointed in the results.”</li><li>The experimental therapy, however, was safe and well-tolerated, the company said.</li><li>Rifaximin is already approved in the U.S. and marketed as Xifaxan.</li></ul>Shares of Bausch Health Companies Inc. (BHC) fell 10% on Friday after the company said that its late-stage program evaluating amorphous-rifaximin solid soluble dispersion (SSD) in adults with liver cirrhosis failed to meet its primary goal.The clinical program <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://ir.bauschhealth.com/news-releases/2026/01-23-2026-124516159">evaluated</a> rifaximin SSD for the delay of the first episode of hepatic encephalopathy (HE) in adults with liver cirrhosis who experienced no prior episodes. The program consisted of two global trials involving more than 1000 patients.Hepatic encephalopathy is a serious brain dysfunction caused by liver failure, where the liver can't remove toxins from the blood, allowing them to build up and affect the brain, causing confusion, personality changes, slurred speech, and lethargy, potentially leading to coma.<h2 class="st-heading-2">Executive Takeaway</h2>CEO Thomas J. Appio said that the company is “disappointed in the results.” The experimental therapy, however, was safe and well-tolerated, the company said.“We are currently reviewing the full dataset to determine potential new development opportunities," he said while adding that the company remains committed to bringing new treatments to patients across hepatology and other therapeutic areas.Rifaximin is already approved in the U.S. and marketed as Xifaxan which is slated to lose exclusivity in 2028. The recent trials were evaluating a new variant of the compound.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment around BHC stock rose from ‘bearish’ to ‘bullish’ territory over the past 24 hours, while retail chatter rose from ‘high’ to ‘extremely high’ levels.A Stocktwits user expressed anticipation for the company’s quarterly report in February, saying the company “lost &nbsp;a &nbsp;Battle but not &nbsp;the &nbsp;war.”<stembedurl>https://www.stocktwits.com/Valmaro/message/642700352</stembedurl>Another user, however, opined that the trial failure is “a serious blow” to the company’s future prospects.<stembedurl>https://www.stocktwits.com/Contrarian_Dan/message/642693387</stembedurl><a href="https://stocktwits.com/symbol/BHC">BHC stock</a> has dropped 24% over the past 12 months.&nbsp;Read More: <a href="https://stocktwits.com/news-articles/markets/equity/tesla-market-share-dives-in-ev-stronghold-california-in-2025-paving-way-for-asian-rivals-growth/cmUCgvWR4X8">Tesla’s Market Share Dives In EV Stronghold California In 2025, Paving Way For Asian Rival’s Growth</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

 In this photo illustration, the Bausch Health logo is displayed on the screen of a tablet. (Photo Illustration by Sheldon Cooper/SOPA Images/LightRocket via Getty Images)

BHC Stock Plummets On Failed Liver Cirrhosis Trial: Retail Says ‘Lost Battle But Not The War’

The failed clinical program evaluated rifaximin SSD for the delay of the first episode of hepatic encephalopathy (HE) in adults with liver cirrhosis who experienced no prior episodes.

<ul class="summary-bullets"><li>The winding down of the said activities will impact about 365 employees across regions including Europe, the U.S. and China, the company said.&nbsp;</li><li>It will also result in the shut down of sites in the Netherlands, Switzerland, U.S. and China.</li><li>Galapagos CFO Aaron Cox had said in November that the company expects to be cash flow neutral to positive by the end of 2026 if the wind down is implemented.</li></ul> Galapagos NV (GLPG) on Monday announced that its Board of Directors has decided to initiate the wind-down of the company’s cell therapy activities, sending shares up 6% in Monday’s after hours trading.The company had announced its intent to wind down the activities after a strategic review and sale process in October but had held on acting on it until it completed communicating with work councils in the Belgium and Netherlands. The winding down of the said activities will impact about 365 employees across regions including Europe, the U.S. and China, the company <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.globenewswire.com/news-release/2026/01/05/3213177/0/en/Galapagos-Announces-Board-Decision-to-Initiate-Wind-Down-of-Cell-Therapy-Activities.html">said</a>.It will also result in the shut down of sites in the Netherlands, Switzerland, the U.S. and China. The U.S. facilities to be shut down include one in Princeton and another in Pittsburgh, the company said. More details about the wind down, including details pertaining to its timeline and costs, will be provided with the company’s full year earnings in February, it added.Galapagos CFO Aaron Cox had said in November that the company expects to be cash flow neutral to positive by the end of 2026 if the wind down is implemented.<h2 class="st-heading-2">Future After Wind Down</h2>On Monday, Galapagos said that the wind-down of the cell therapy activities will position it for longer-term growth. The company will continue to manage its non-cell therapy programs and evaluate all strategic alternatives for GLPG3667, an investigational, oral, selective inhibitor of tyrosine kinase 2, to accelerate its development in dermatomyositis and potentially other severe auto-immune indications, the company said.The company will also consider resuming the partnering process for the drug, it said. Galapagos also added that it will continue to maintain its presence at its headquarters in Belgium as well as its hubs in Chicago and San Francisco.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, the retail sentiment about GLPG stayed in the ‘neutral’ territory over the past 24 hours, while message volume stayed at ‘high’ levels.<a href="https://stocktwits.com/symbol/GLPG">GLPG stock</a> has gained 15% over the past 12 months.&nbsp;Read also: <a href="https://stocktwits.com/news-articles/markets/equity/toyota-us-sales-rise-8-percent-in-q4/cmxMCZPR4Ri">US Heeds Trump To Buy A Toyota: Japanese Automaker’s US Sales Rise 8% In Q4</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

A logo of Galapagos, a European pharmaceutical research company, is pictured outside its facility on June 9, 2020 in Leiden, Netherlands. (Photo by Yuriko Nakao/Getty Images) 

Galapagos Stock Rises After Hours On Starting To Wind Down Cell Therapy Activities, Subsequent Workforce Reduction 

The company had announced its intent to wind down the activities after a strategic review and sale process in October.

<ul class="summary-bullets"><li>Baytex Energy announced a target of 3% to 5% annual production growth, targeted to reach about 75,000 boe/d in 2028.&nbsp;</li><li>The company said it plans to return a significant portion of Eagle Ford’s $2.14 billion in sale proceeds to shareholders.&nbsp;</li><li>It appointed Chad E. Lundberg as the President and Chief Operating Officer from Dec. 22, 2025.</li></ul>Baytex Energy Corp. (BTE) is setting the stage for growth in 2026 with a $625 million capital budget and plans to return a significant part of its Eagle Ford sale proceeds to shareholders. Additionally, the announcement of a new leadership signals a shift in priorities for the year ahead.Shares of BTE climbed over 2% in Monday's pre-market trade.<h2 class="st-heading-2">Capital Budget Usage</h2>Baytex Energy announced a capital budget of $550 to $625 million for 2026, a target of 3% to 5% production growth reaching about 75,000 barrels of oil equivalent per day (boe/d) in 2028.The company’s 2026 exploration and development budget aims to generate an average annual production of 67,000 to 69,000 boe/d and is expected to deliver 3% to 5% production growth from 2025 levels.Of this, about 55% of the budget will be allocated to light oil assets, and the remaining 45% to heavy oil assets, the company said. Production in the first quarter (Q1) of 2026 is expected to average 68,000 to 69,000 boe/d, with plans to scale to 70,000 boe/d at the end of the year. The company also plans to bring 91 heavy-oil wells onstream, with 2026 production averaging 43,000 to 44,000 bbl/d.Of the total capital expenses, $50 to $75 million growth capital will be focused on the Pembina Duvernay and northeast Alberta Mannville, $50 million will be directed towards infrastructure investment that will include anchor oil batteries and water infrastructure in the Pembina Duvernay, and gas conservation in Peace River, and another $50 million will go towards exploration and land investments, the company said."Looking ahead, we are targeting 3% to 5% annual production growth while investing in exploration and infrastructure for future development. Supported by our industry-leading net cash balance sheet, we are prioritizing shareholder returns in 2026," Eric T. Greager, Chief Executive Officer of Baytex Energy, said.<h2 class="st-heading-2">Sale Proceeds And Executive Charges</h2>Baytex Energy completed the sale of its U.S. Eagle Ford Assets for $2.14 billion on December 19, and plans to return a significant portion of the proceeds to shareholders.The company also reaffirmed its annual dividend guidance of $0.09 per share, subject to Board of Directors approval.Additionally, the energy company announced that Chad E. Lundberg will take over as President and Chief Operating Officer from Dec. 22, 2025.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment around BTE stock remained in the ‘neutral’ territory over the past 24 hours, while message volume stayed at ‘normal’ levels at the time of writing.<figure class="image"><img style="aspect-ratio:1291/159;" src="https://news.stocktwits-cdn.com/Baytex_sentiment_png_47e2fce461.webp" alt="On Stocktwits, retail sentiment around BTE stock remained in the ‘neutral’ territory over the past 24 hours, while message volume stayed at ‘normal’ levels at the time of writing." width="1291" height="159"></figure>Shares of BTE have gained over 25% in the past one year.For updates and corrections, email newsroom[at]stocktwits[dot]com.

CANADA - 2025/09/17: In this photo illustration, the Baytex Energy Corp. logo is seen displayed on a smartphone screen. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images)

Baytex Energy Sets 2026 Capital Spending, Growth Targets – And Names New COO

The company announced a capital budget of up to $625 million for 2026, with 55% allocated to light oil assets and 45% to heavy oil assets.

Retail investors on Stocktwits are optimistic about Genius Group’s pivot and hope to see the same returns as MicroStrategy after the latter pivoted to a Bitcoin-first strategy in 2020. | Source: Pixabay

Why Is Genius Group Stock Rising Today?

Genius Group repurchased its stock on the open market at an average price of $0.90 per share from August 28 to September 11, 2025.

Global Equity ETFs Draw Rising Investor Interest

Global equity funds saw $10.65B inflows as Fed rate cut bets, a weak dollar and diversification needs drive investors abroad.

SPDR Index Shares Funds - State Street SPDR Portfolio Developed World ex-US ETF

Opendoor ($OPEN)

Strategy ($MSTR)

American Eagle ($AEO)

Ondas Inc. ($ONDS)

The stock that proved the power of the crowd. Fueled by community energy and social momentum, this winner captivated retail investors regardless of what the "experts" or traditional fundamentals had to say.

SPDW
SPDR Portfolio Developed World ex-US ETF

Feed

News

Sentiment

Fundamentals

Info

Poll

Latest SPDW News

SPDWSPDR Portfolio Developed World ex-US ETF